Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Blood

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 9787160
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.

  1998cited by this paper
• Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men.

  1997cited by this paper
• Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.

  1997cited by this paper
• GPIIb/IIIa Antagonists: Pathophysiologic and Therapeutic Insights from Studies of c7E3 Fab

  1997cited by this paper
• Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets.

  1996cited by this paper
• Immunological characterization of eristostatin and echistatin binding sites on alpha IIb beta 3 and alpha V beta 3 integrins.

  1996cited by this paper
• Pentamidine Is a Specific, Non-Peptide, GPIIb/llla Antagonist

  1996cited by this paper
• Differential Inhibition of Fibrinogen Binding to Agonist-and RGDS Peptide-activated States of GPIIb-IIIa by an anti-GPIIIa Monoclonal Antibody, PMA5

  1996cited by this paper
• Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.

  1996cited by this paper
• Modulation of cell migration by integrin-mediated cytoskeletal linkages and ligand-binding affinity

  1996cited by this paper
• Modulation of cell adhesion by changes in alpha L beta 2 (LFA-1, CD11a/CD18) cytoplasmic domain/cytoskeleton interaction

  1995cited by this paper
• Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators.

  1995cited by this paper
• Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine.

  1995influential reference
• Mutation of the cytoplasmic domain of the integrin beta 3 subunit. Differential effects on cell spreading, recruitment to adhesion plaques, endocytosis, and phagocytosis.

  1995cited by this paper
• Integrins and signal transduction pathways: the road taken.

  1995cited by this paper
• Clues for Understanding the Structure and Function of a Prototypic Human Integrin: The Platelet Glycoprotein IIb/IIIa Complex

  1994cited by this paper
• Integrin cytoplasmic domains mediate inside-out signal transduction

  1994cited by this paper
• Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

  1994cited by this paper
• Aspirin, platelets, and thrombosis: theory and practice.

  1994cited by this paper
• Tetrafibricin, a novel non-peptide fibrinogen receptor antagonist, induces conformational changes in glycoprotein IIb/IIIa.

  1994cited by this paper
• Distinct functions of integrin alpha and beta subunit cytoplasmic domains in cell spreading and formation of focal adhesions

  1993cited by this paper
• Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa.

  1993cited by this paper
• The Arg-Gly-Asp (RGD) recognition site of platelet glycoprotein IIb-IIIa on nonactivated platelets is accessible to high-affinity macromolecules.

  1992cited by this paper
• Integrins: versatility, modulation, and signaling in cell adhesion.

  1992cited by this paper
• Identification of the disulfide bond pattern in albolabrin, an RGD-containing peptide from the venom of Trimeresurus albolabris: significance for the expression of platelet aggregation inhibitory activity.

  1991cited by this paper
• Modulation of the affinity of integrin alpha IIb beta 3 (GPIIb-IIIa) by the cytoplasmic domain of alpha IIb.

  1991cited by this paper
• Ligands "activate" integrin alpha IIb beta 3 (platelet GPIIb-IIIa).

  1991cited by this paper
• Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers.

  1990cited by this paper
• Affinity modulation of the alpha IIb beta 3 integrin (platelet GPIIb-IIIa) is an intrinsic property of the receptor.

  1990cited by this paper
• Binding of the snake venom-derived proteins applaggin and echistatin to the arginine-glycine-aspartic acid recognition site(s) on platelet glycoprotein IIb.IIIa complex inhibits receptor function.

  1990cited by this paper
• A monoclonal antibody against the platelet fibrinogen receptor contains a sequence that mimics a receptor recognition domain in fibrinogen.

  1989cited by this paper
• Occupancy of an adhesive glycoprotein receptor modulates expression of an antigenic site involved in cell adhesion.

  1988cited by this paper
• Synthetic peptides derived from fibrinogen and fibronectin change the conformation of purified platelet glycoprotein IIb-IIIa.

  1987cited by this paper
• Activation affects access to the platelet receptor for adhesive glycoproteins

  1986cited by this paper
• Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation.

  1985cited by this paper
• The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets.

  1985cited by this paper
• A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex.

  1985cited by this paper

• Targeting integrin pathways: mechanisms and advances in therapy

  2023cites this paper
• Pathophysiology of COVID-19: Critical Role of Hemostasis

  2022cites this paper
• Dual‐target synergistic antithrombotic mechanism of a dabigatran etexilate analogue (HY023016)

  2022cites this paper
• How not to discover a drug - integrins

  2020cites this paper
• Effects of water-soluble tomato concentrate on platelet aggregation

  2019cites this paper
• Platelet decoys inhibit thrombosis and prevent metastatic tumor formation in preclinical models

  2019cites this paper
• Biomechanical thrombosis: the dark side of force and dawn of mechano-medicine

  2019cites this paper
• Off-target drug effects on platelet function: Protecting an Achilles heel of drug development

  2019cites this paper
• Current and future antiplatelet therapies: emphasis on preserving haemostasis

  2018cites this paper
• Measurement of platelet aggregation, independently of patient platelet count: a flow‐cytometric approach

  2017cites this paper
• Intercellular Interactions as Regulators of NETosis

  2016influential citation
• How abciximab might be clinically useful.

  2016cites this paper
• Myocardial Ischemia and Infarction lopidogrel Inhibits Platelet-Leukocyte nteractions and Thrombin Receptor gonist Peptide-Induced Platelet Activation n Patients With an Acute Coronary Syndrome

  2016cites this paper
• The integrin antagonist, cilengitide, is a weak inhibitor of αIIbβ3 mediated platelet activation and inhibits platelet adhesion under flow

  2015cites this paper
• Targeting Integrin and Integrin Signaling in Treating Thrombosis

  2015cites this paper
• Towards Effective and Safe Thrombolysis and Thromboprophylaxis: Preclinical Testing of a Novel Antibody-Targeted Recombinant Plasminogen Activator Directed Against Activated Platelets

  2014cites this paper
• Integrin &agr;IIb&bgr;3: From Discovery to Efficacious Therapeutic Target

  2013cites this paper
• 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cites this paper
• EM Structure of the Ectodomain of Integrin CD11b/CD18 and Localization of Its Ligand-Binding Site Relative to the Plasma Membrane

  2013cites this paper
• Treatment for Type IV Coronary Perforation during Percutaneous Coronary Intervention

  2013cites this paper
• Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury.

  2013cites this paper
• Tratamento de perfuração coronária tipo IV durante intervenção coronária percutânea

  2013cites this paper
• GPIIb/IIIa inhibitors: From bench to bedside and back to bench again

  2012cites this paper
• Structure-Guided Design of a High-Affinity Platelet Integrin αIIbβ3 Receptor Antagonist That Disrupts Mg2+ Binding to the MIDAS

  2012cites this paper
• 'Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel' – a hypothesis that remains unproven

  2012cites this paper
• Flow cytometry analysis of porcine platelets: Optimized methods for best results

  2012cites this paper
• Platelet signalling networks: Pathway perturbation demonstrates differential sensitivity of ADP secretion and fibrinogen binding

  2012cites this paper
• A novel anti-platelet peptide (Z4A5) potential for glycoprotein IIb/IIIa inhibits platelet aggregation.

  2012cites this paper
• An insight into the sialotranscriptome of Triatoma matogrossensis, a kissing bug associated with fogo selvagem in South America.

  2012cites this paper
• 2012 ACCF/AHA Focused Update Incorporated Into the ACCF/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2011cites this paper
• Cystine‐knot peptides engineered with specificities for αIIbβ3 or αIIbβ3 and αvβ3 integrins are potent inhibitors of platelet aggregation

  2011cites this paper
• 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2011cites this paper
• 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in c

  2011cites this paper
• Antiplatelet effects of Spatholobus suberectus via inhibition of the glycoprotein IIb/IIIa receptor.

  2011cites this paper
• Stable Coordination of the Inhibitory Ca2+ Ion at the Metal Ion-Dependent Adhesion Site in Integrin CD11b/CD18 by an Antibody-Derived Ligand Aspartate: Implications for Integrin Regulation and Structure-Based Drug Design

  2011cites this paper
• Closed headpiece of integrin αIIbβ3 and its complex with an αIIbβ3-specific antagonist that does not induce opening.

  2010cites this paper
• Current strategies in antiplatelet therapy--does identification of risk and adjustment of therapy contribute to more effective, personalized medicine in cardiovascular disease?

  2010cites this paper
• Antagonism of P2Y12 or GPIIb/IIIa receptors reduces platelet-mediated myocardial injury after ischaemia and reperfusion in isolated rat hearts

  2010cites this paper
• Targeting the platelet integrin GPIIb/IIIa.

  2010cites this paper
• Leukocyte integrins and their ligand interactions

  2009cites this paper
• Outside-In Signal Transmission by Conformational Changes in Integrin Mac-11

  2009cites this paper
• PLATELET DYSFUNCTION AND PROCOAGULANT ACTIVITY IN DIABETES MELLITUS

  2009cites this paper
• Integrin priming dynamics: mechanisms of integrin antagonist-promoted alphaIIbbeta3:PAC-1 molecular recognition.

  2009cites this paper
• Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.

  2009cites this paper
• Novel Strategies in Anti-Platelet Treatment for Coronary Artery Disease

  2009cites this paper
• Antiplatelet and antithrombotic activity of indole‐3‐carbinol in vitro and in vivo

  2008cites this paper
• FcgammaRII mediates platelet aggregation caused by disintegrins and GPIIb/IIIa monoclonal antibody, AP2.

  2008cites this paper
• Platelet hyperprocoagulant activity in Type 2 diabetes mellitus: attenuation by glycoprotein IIb/IIIa inhibition

  2008cites this paper
• Type 3 phosphodiesterase inhibitors may be protective against cerebrovascular events in patients with claudication.

  2008cites this paper
• Interaction and functional association of protein disulfide isomerase with αVβ3 integrin on endothelial cells

  2008cites this paper
• [Guidelines of the American College of Cardiology/American Heart Association 2007 for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Part VI].

  2008cites this paper
• Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.

  2008cites this paper
• Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials

  2008cites this paper
• Therapeutic Inhibitors of Platelet Aggregation – from Aspirin to Integrin Blockersf

  2007cites this paper
• Literatur zum Artikel: Schwarz

  2007cites this paper
• A Mechanistic Model for Paradoxical Platelet Activation by Ligand-Mimetic &agr;IIb&bgr;3 (GPIIb/IIIa) Antagonists

  2007cites this paper
• A mechanistic model for paradoxical platelet activation by ligand-mimetic alphaIIb beta3 (GPIIb/IIIa) antagonists.

  2007cites this paper
• ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie

  2007cites this paper
• Activation of Platelet Function Through G Protein–Coupled Receptors Platelets As Immune Cells: Bridging Inflammation and Cardiovascular Disease In Vivo Thrombus Formation in Murine Models Clinical Aspects of Platelet Inhibitors and Thrombus Formation Platelet Adhesion

  2007cites this paper
• Single-chain antibodies as new antithrombotic drugs.

  2007cites this paper
• Single-Chain Antibodies as New Antithrombotic Drugs

  2007cites this paper
• Pharmacogenetics of antithrombotic drugs.

  2006cites this paper
• New approaches to blockade of alpha4-integrins, proven therapeutic targets in chronic inflammation.

  2006cites this paper
• Prevention of Platelet Glycoprotein IIb/IIIa Activation by 3,4-Methylenedioxy-β-Nitrostyrene, A Novel Tyrosine Kinase Inhibitor

  2006cites this paper
• Conformation-Specific Blockade of the Integrin GPIIb/IIIa: A Novel Antiplatelet Strategy That Selectively Targets Activated Platelets

  2006cites this paper
• Recombinant P‐selectin glycoprotein‐ligand‐1 delays thrombin‐induced platelet aggregation: a new role for P‐selectin in early aggregation

  2006cites this paper
• Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin.

  2006cites this paper
• Drug-induced thrombocytopenia and thrombosis: Evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial

  2006cites this paper
• Xemilofiban/orbofiban: insight into drug development.

  2006cites this paper
• Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.

  2006cites this paper
• [Platelet function after a high dose bolus of tirofiban immediately after coronary angioplasty].

  2006cites this paper
• Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting.

  2006cites this paper
• Determinants of the interindividual variability in response to antiplatelet drugs

  2005cites this paper
• Glycoprotein IIb/IIIa inhibition reduces prothrombotic events under conditions of deep hypothermic circulatory arrest

  2005cites this paper
• GPIIb–IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention

  2005cites this paper
• FK419, a Novel Nonpeptide GPIIb/IIIa Antagonist, Restores Microvascular Patency and Improves Outcome in the Guinea-Pig Middle Cerebral Artery Thrombotic Occlusion Model: Comparison with Tirofiban

  2005cites this paper
• Abciximab therapy is associated with increased platelet activation and decreased heparin dosage in patients with acute myocardial infarction

  2005cites this paper
• Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors.

  2005cites this paper
• A novel anti-platelet monoclonal antibody (3C7) specific for the complex of integrin alpha IIb beta3 inhibits platelet aggregation and adhesion.

  2005cites this paper
• Impact of Platelet Glycoprotein IIb/IIIa Inhibitor Therapy on In-Hospital Outcomes and Long-Term Survival Following Percutaneous Coronary Rotational Atherectomy

  2005cites this paper
• Abciximab Does Not Inhibit the Increase of Thrombin Generation Produced in Platelet-Rich Plasma In Vitro by Sodium Arachidonate or Tissue Factor

  2005cites this paper
• Platelet Integrins and Signaling

  2005cites this paper
• Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study.

  2005cites this paper
• Embryonic stem cell differentiation : a novel approach to gene targeting in myeloid cells

  2005cites this paper
• Thrombocytopenia resulting from sensitivity to GPIIb-IIIa inhibitors.

  2004cites this paper
• Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios

  2004cites this paper
• Distinct roles of ligand affinity and cytoskeletal anchorage in alphaIIbbeta3 (GP IIb/IIIa)-mediated cell aggregation and adhesion.

  2004cites this paper
• Lessons Learned From a Clinical Trial

  2004cites this paper
• [Expert consensus document on the use of antiplatelet agents].

  2004cites this paper
• Platelet dysfunction during Bothrops jararaca snake envenomation in rabbits

  2004cites this paper
• Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome.

  2004cites this paper
• Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

  2004cites this paper
• RGDS peptide induces caspase 8 and caspase 9 activation in human endothelial cells.

  2004cites this paper
• Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.

  2004cites this paper
• Oral GPIIb/IIIa antagonists: what went wrong?

  2004cites this paper
• Reversibility versus Persistence of GPIIb/IIIa Blocker-Induced Conformational Change of GPIIb/IIIa (αIIbβ3, CD41/CD61)

  2004influential citation
• Attachment of hyaluronan to metallic surfaces.

  2004cites this paper
• Platelet-active drugs : the relationships among dose, effectiveness, and side effects.

  2004cites this paper
• Delayed immunologic thrombocytopenia induced by abciximab

  2004cites this paper
• Distinct roles of ligand affinity and cytoskeletal anchorage in αIIbβ3 (GP IIb/IIIa)-mediated cell aggregation and adhesion

  2004cites this paper